‍

Silversmith Capital Partners’ Jeff Crisan was named as a Top 25 Healthcare Investor of 2022 by GrowthCap Advisory. With over 800 nominees this year, GrowthCap evaluated each based on the quality of feedback they received from portfolio company CEOs, firm colleagues and peers in the industry, as well as their own proprietary research. The 2022 list represents a diverse set of individuals with demonstrated exceptional performance in the areas of investment selection, value creation, and ESG engagement.

As noted by GrowthCap, “Healthcare plays a critical role in the quality of our lives, underpins business and economic activity, and ultimately determines the state of our world. This year’s awardees were selected based on deal experience and track record, strategic and operational capabilities provided to portfolio companies, unique and differentiated attributes, as well as contributions to ESG, DEI, charitable work, and overall industry advancement.”

Jeff co-founded Silversmith Capital Partners in 2015. In his role as Managing Partner, Jeff focuses on investments in Healthcare IT & Services. Within Healthcare IT, Jeff partners with talented leaders of proven, high growth software and data companies that can either materially improve clinical outcomes or reduce administrative inefficiency within all segments of the U.S. healthcare ecosystem. Jeff’s healthcare services investments are centered around innovative care delivery models oriented towards value-based care that can be scaled both organically and through M&A.

With more than 20 years investing experience, Jeff has led many of the firm’s key healthcare investments including Iodine Health, LifeStance Health (Nasdaq: LFST), MediQuant, Nordic, Panalgo (acquired by MMIT/Evaluate), Partners Surgical, Sound Physicians, Upperline Health, US Health Partners and Within3. Some of Jeff’s notable investments prior to founding Silversmith include ABILITY Network, Liberty Dialysis, Liazon and MedHOK.  

Read more about Jeff and his fellow honorees here.

The Firm Recognitions presented herein are from third-parties that are not affiliated with Silversmith. These third-parties independently assess nominees based on multiple criteria. The awards and designations presented on this website are the opinion of the respective parties conferring the award or designation and not of Silversmith. Recognitions by third-parties are not indicative of future performance. Silversmith pays a licensing or related fee to participate and/or distribute the results. The receipt of compensation influences, and is likely to present a potential material conflict of interest, relating to any granted award or designation. There can be no assurance that other providers or surveys would reach the same conclusions as the foregoing.  

Silversmith submitted nominations to be considered for the GrowthCap Top 25 Healthcare Investors of 2022 award and has paid a fee to promote this award. For additional details on the award selection criteria and methodology, please visit https://growthcapadvisory.com/the-top-25-healthcare-investors-of-2022/